Key Facts

Invested since 2014
Based in North Rhine-Westphalia

About the company

Rigontec GmbH, is a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Rigontec focus on the development of synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I promote the destruction of diseased cells and the induction of a lasting immune memory thereby treating and preventing recurrence of disease.

Rigontec’s, a proprietary first-in-class product targeting RIG-I, is currently being evaluated for development in several cancer types including melanoma and prostate cancer. ImOl100 is a chemically synthesized mimic of the natural ligand of RIG-I with improved safety and drug like properties. In various preclinical models, ImOl100 has demonstrated substantial tumor regression and systemic anti-tumor activity including long-term protection against tumor rechallenge. Rigontec’s technology also allows the design of pipeline candidates with additional gene silencing and inhibitory activities. Rigontec is financed by top-tier VC investors and is seeking to realize the full potential of its technology by developing an internal pipeline into the clinic.

Do you want to

know more about this company?

Zum Artikel

Dr. Caroline Fichtner Principal

Dr. Caroline FichtnerPrincipal

Rigontec in the news

Zum Artikel

News

6. September 2016

Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics

Zum Artikel

Press

24. March 2015

Rigontec GmbH raises €4.8m in a second closing of its Series A financing

Zum Artikel

Press

14. October 2014

Rigontec GmbH raises € 9.45 m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases

More startups from Life Sciences